Umarell Pharma Consulting
Connecting the dots from idea to revenue in generic pharma
Umarell offers a steady hand to strengthen competitiveness and deliver long-term growth in generic pharma, based on a profound end-to-end understanding of the generic pharma value chain from idea to revenue stream.
We deliver commercially grounded solutions and advisory based on a rare combination of hands-on pharma business experience, understanding of compliance requirements, and respect for the complexity in running a pharma business long term and on a daily basis.
Services
Growth, partnerships, and execution
Umarell helps manage internal and external partnerships and cross-functional teams to expand business, and to integrate and support opportunities and initiatives all over the value chain.
Compliance-aware decision support
Umarell has a deep understanding and respect for compliance requirements and harsh reality, delivering sound, data-driven C-level decisions, aligned across key stakeholders.
End-to-end value chain perspective
From early idea through portfolio and pipeline work to commercialisation and revenue streams, we connect the dots to ensure decisions are feasible, aligned, and commercially robust.
About
What “Umarell” means
“Umarell” is Italian slang for the elder men passing their time by standing outside the fence around construction sites offering helpful advice – with scolding remarks – to the workers inside.
About Christian Gyde
Christian Gyde has 25+ years of experience building successful pharma businesses across manufacturing, commercial operations, development, and corporate development. He has led and supported growth initiatives across the generic value chain, including pipeline and portfolio work, partnerships, and strategic execution.
His background spans from building the family business Ophtha A/S as co-owner (manufacturing and marketing ophthalmic pharmaceuticals in Denmark and Norway), the subsequent sale to Actavis Denmark A/S (continuing on-board), and later senior leadership roles at Orifarm Generics A/S and Orifarm Group, including Vice President responsibility within Development/Pipeline and Corporate Development.